OBJECTIVES: To compare the tigecycline activity profile against Acinetobacter spp. by Etest versus broth microdilution in isolates with high Etest MIC. METHODS: Acinetobacter spp. isolates with tigecycline MICs of >or=0.5 mg/L determined by commercially developed Etests strips (January 2006 to July 2007) in five Spanish hospitals were considered. Values were rounded to the nearest upper double-dilution. Susceptibility by broth microdilution following CLSI (formerly NCCLS) recommendations, as the reference method, was determined in a central laboratory. BSAC breakpoints were used: susceptible <or=1 mg/L; intermediate = 2 mg/L; and resistant >2 mg/L. RESULTS: One hundred and forty-eight isolates were collected: 12 isolates with a tigecycline Etest MIC of 0.5 mg/L, 14 with 1 mg/L, 86 with 2 mg/L, 31 with 4 mg/L and 5 with 8 mg/L. Isolates with Etest MICs of 0.5-1 mg/L showed the same values by broth microdilution. Among isolates with Etest MICs of 2 mg/L, only 5.8% of strains showed the same value by both methods (88.4% showed values that were one or two dilutions lower by microdilution). None of the 36 isolates with Etest MICs of 4-8 mg/L showed the same value by both methods, with values at least two dilutions lower by microdilution. Weak correlation (R = 0.238; P <or= 0.001) was found between both methods. All 26 Etest susceptible isolates, 80/86 (93.0%) Etest intermediate and 32/36 (88.9%) Etest resistant strains were susceptible by microdilution. CONCLUSIONS: Caution should be taken in interpreting Etest MICs of >or=2 mg/L for Acinetobacter spp. since strains with Etest MICs of 2-4 mg/L are susceptible when tested by microdilution. False non-susceptibility by Etest may exclude tigecycline as a therapeutic option in a field where multiresistance is the rule.
OBJECTIVES: To compare the tigecycline activity profile against Acinetobacter spp. by Etest versus broth microdilution in isolates with high Etest MIC. METHODS: Acinetobacter spp. isolates with tigecycline MICs of >or=0.5 mg/L determined by commercially developed Etests strips (January 2006 to July 2007) in five Spanish hospitals were considered. Values were rounded to the nearest upper double-dilution. Susceptibility by broth microdilution following CLSI (formerly NCCLS) recommendations, as the reference method, was determined in a central laboratory. BSAC breakpoints were used: susceptible <or=1 mg/L; intermediate = 2 mg/L; and resistant >2 mg/L. RESULTS: One hundred and forty-eight isolates were collected: 12 isolates with a tigecycline Etest MIC of 0.5 mg/L, 14 with 1 mg/L, 86 with 2 mg/L, 31 with 4 mg/L and 5 with 8 mg/L. Isolates with Etest MICs of 0.5-1 mg/L showed the same values by broth microdilution. Among isolates with Etest MICs of 2 mg/L, only 5.8% of strains showed the same value by both methods (88.4% showed values that were one or two dilutions lower by microdilution). None of the 36 isolates with Etest MICs of 4-8 mg/L showed the same value by both methods, with values at least two dilutions lower by microdilution. Weak correlation (R = 0.238; P <or= 0.001) was found between both methods. All 26 Etest susceptible isolates, 80/86 (93.0%) Etest intermediate and 32/36 (88.9%) Etest resistant strains were susceptible by microdilution. CONCLUSIONS: Caution should be taken in interpreting Etest MICs of >or=2 mg/L for Acinetobacter spp. since strains with Etest MICs of 2-4 mg/L are susceptible when tested by microdilution. False non-susceptibility by Etest may exclude tigecycline as a therapeutic option in a field where multiresistance is the rule.
Authors: J Veenemans; J W Mouton; J A J W Kluytmans; R Donnely; C Verhulst; P H J van Keulen Journal: J Clin Microbiol Date: 2012-06-20 Impact factor: 5.948
Authors: James Cohen Stuart; Johan W Mouton; Bram M W Diederen; Nashwan Al Naiemi; Steven Thijsen; Bart J M Vlaminckx; Ad C Fluit; Maurine A Leverstein-van Hall Journal: Antimicrob Agents Chemother Date: 2010-03-29 Impact factor: 5.191
Authors: M Torrico; N González; M J Giménez; L Alou; D Sevillano; D Navarro; M P Díaz-Antolín; N Larrosa; L Aguilar; N Garcia-Escribano Journal: J Clin Microbiol Date: 2010-03-29 Impact factor: 5.948
Authors: Tara Reddy; Teena Chopra; Dror Marchaim; Jason M Pogue; George Alangaden; Hossein Salimnia; Dina Boikov; Shiri Navon-Venezia; Robert Akins; Philip Selman; Sorabh Dhar; Keith S Kaye Journal: Antimicrob Agents Chemother Date: 2010-03-08 Impact factor: 5.191
Authors: Dror Marchaim; Jason M Pogue; Oran Tzuman; Kayoko Hayakawa; Paul R Lephart; Hossein Salimnia; Theresa Painter; Marcus J Zervos; Laura E Johnson; Mary Beth Perri; Pamela Hartman; Rama V Thyagarajan; Sharon Major; Melanie Goodell; Mohamad G Fakih; Laraine L Washer; Duane W Newton; Anurag N Malani; Jason M Wholehan; Lona Mody; Keith S Kaye Journal: J Clin Microbiol Date: 2014-03-05 Impact factor: 5.948